Computational design and biophysical validation of macrocyclic peptides as inhibitors of SLIT2/ROBO1 interaction
Bioorganic & Medicinal Chemistry Letters · 2026-08 · 137 · 130656
DOI: 10.1016/j.bmcl.2026.130656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-08. Verfasst von Somaya A Abdel-Rahman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA; Department of Medicinal Chem…. Hauptthemen laut MEDLINE: Nerve Tissue Proteins, Intercellular Signaling Peptides and Proteins, Drug Design, Receptors, Immunologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
The SLIT2/ROBO1 signaling axis regulates cellular migration and angiogenesis but also contributes to tumor progression and immune evasion in glioblastoma. Targeting this pathway with small molecules or antibodies remains challenging due to the shallow and extended nature of the SLIT2/ROBO1 interface. Here, we report the first computational design and experimental validation of macrocyclic peptides that inhibit SLIT2/ROBO1 binding. Twenty peptides were generated through a structure-guided interface mapping approach (Des3PI 2.0) and ranked using a contact-based scoring function. The top candidates were synthesized and evaluated using time-resolved fluorescence resonance energy transfer (TR-FRET) and biolayer interferometry (BLI) assays. Among the SLIT2-targeting peptides, SP4 and SP3 showed the most pronounced inhibition in TR-FRET (62% and 46%, respectively), with dose-dependent IC₅₀ values of 41 ± 5.2 μM and 68 ± 7.5 μM by BLI, confirming direct binding to the SLIT2/ROBO1 interface. The lead peptide SP4 also demonstrated favorable in vitro pharmacokinetic properties, including strong stability in simulated intestinal fluid (t₁/₂ = 7.6 h), high plasma integrity (89% at 1 h), and moderate metabolic stability in rat liver microsomes (t₁/₂ = 4.7 h). Collectively, this work provides a foundation for developing next-generation SLIT2/ROBO1 modulators for cancer and neuroimmune disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
- Université Paris-Saclay, CNRS, BioCIS, Orsay, France.
- Université Paris-Saclay, CNRS, BioCIS, Orsay, France. Electronic address: tap.ha-duong@universite-paris-saclay.fr.
- Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: mog4005@med.cornell.edu.
Zitieren
APA
Abdel-Rahman, S. A., Delaunay, M., Ha-Duong, T., & Gabr, M. (2026). Computational design and biophysical validation of macrocyclic peptides as inhibitors of SLIT2/ROBO1 interaction. Bioorganic & Medicinal Chemistry Letters, 137, 130656. https://doi.org/10.1016/j.bmcl.2026.130656
Vancouver
Abdel-Rahman SA, Delaunay M, Ha-Duong T, Gabr M. Computational design and biophysical validation of macrocyclic peptides as inhibitors of SLIT2/ROBO1 interaction. Bioorganic & Medicinal Chemistry Letters. 2026;137:130656. doi:10.1016/j.bmcl.2026.130656
BibTeX
@article{AbdelRahman2026,
author = {Abdel-Rahman, Somaya A and Delaunay, Maxence and Ha-Duong, Tâp and Gabr, Moustafa},
title = {Computational design and biophysical validation of macrocyclic peptides as inhibitors of SLIT2/ROBO1 interaction},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {137},
pages = {130656},
doi = {10.1016/j.bmcl.2026.130656}
}
EUVIMED